Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.

Anne Tournadre (1) , Bruno Pereira (2) , Jean-Jacques Dubost (3) , Nathalie Rincheval (4) , Anne Christine Rat (5) , Bernard Combe (6) , Martin Soubrier (1)

1 UNH - Unité de Nutrition Humaine
2 DRCI - Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand]
3 Service de Rhumatologie [CHU Clermont-Ferrand]
4 AIDMP - Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415
5 CHU Caen
6 IGMM - Institut de Génétique Moléculaire de Montpellier

Reduction of LDL-cholesterol (LDLc) is essential to decrease the cardiovascular mortality in rheumatoid arthritis (RA). Between 2005 and 2010, French recommendations for dyslipidaemia defined the LDLc target based on the number of cardiovascular risk factors. In 2006, it was recommended to consider LDLc objectives with RA being counted as an additional cardiovascular risk factor. Our objective was to assess lipid target achievement between 2006 and 2010 in a cohort of patients with recent-onset RA.

Domaines: Rhumatologie et système ostéo-articulaire

Anne Tournadre, Bruno Pereira, Jean-Jacques Dubost, Nathalie Rincheval, Anne Christine Rat, et al.. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.. Clinical and experimental rheumatology, 2017, 35 (2), pp.296-302. ⟨hal-02880479⟩